search
Back to results

Pharmacokinetics of BIBR 277 in Hypertensive Patients

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Low dose of BIBR 277
Medium dose of BIBR 277
High dose of BIBR 277
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age: >=20 years
  • Sex: Either male or female
  • Patient status: Either inpatient or outpatient, provided that the patient was available for hospitalisation from the day before the trial medication administration until the morning of the day after administration
  • BP: Sitting systolic and diastolic blood pressures (SBP and DBP) taken the day before administration should be >= 150 mmHg and >= 90 mmHg, respectively. Patients undergoing treatment with other antihypertensives were not excluded provided the above criteria were satisfied.

Exclusion Criteria:

  • Malignant hypertension
  • Renovascular hypertension
  • Severe heart failure (NYHA functional class III - IV), unstable angina pectoris, or history of myocardial infarction (within 6 months of onset)
  • Atrioventricular conduction disturbance (degree II to III), atrial fibrillation, or serious arrhythmia
  • Symptoms of cerebrovascular disorder
  • Serious hepatic dysfunction
  • Renal function disorder (serum creatinine >= 4.0 mg/dL)
  • Known hypersensitivity to angiotensin II receptor antagonists
  • Hyperkalaemia (potassium >= 5.5 milliequivalents per liter (mEq/L))
  • Treatment with the other investigational drug within 6 months of initiation of the present study
  • Pregnant, breast feeding, possibly pregnant or planning to become pregnant during this study
  • Previous treatment with the trial medication of the present study
  • Otherwise judged ineligible by the investigator

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Experimental

    Experimental

    Arm Label

    Low dose of BIBR 277

    Medium dose of BIBR 277

    High dose of BIBR 277

    Arm Description

    Outcomes

    Primary Outcome Measures

    Area under the concentration-time curve of BIBR 277 in plasma from 0 to 24 hours (AUC0-24hr)
    Mean residence time of BIBR 277 in the body from 0 to 24 hours (MRT0-24hr)
    Maximum measured concentration of BIBR 277 in plasma (Cmax)
    Time from dosing to the maximum concentration of BIBR 277 in plasma (tmax)
    Terminal elimination half-time of BIBR 277 in plasma (t1/2)

    Secondary Outcome Measures

    Changes from baseline in blood pressure (systolic, diastolic, and mean)
    Changes from baseline in pulse rate
    Number of patients with adverse events
    Changes from baseline in laboratory test values

    Full Information

    First Posted
    July 9, 2014
    Last Updated
    July 9, 2014
    Sponsor
    Boehringer Ingelheim
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02187497
    Brief Title
    Pharmacokinetics of BIBR 277 in Hypertensive Patients
    Official Title
    BIBR 277 Capsules Pharmacokinetics Study of Hypertensive Patients
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    June 1998 (undefined)
    Primary Completion Date
    September 1998 (Actual)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Boehringer Ingelheim

    4. Oversight

    5. Study Description

    Brief Summary
    The pharmacokinetic profile of BIBR 277 single dose given in capsule form to hypertensives was evaluated. The results of the present study are to be used in the Japanese population pharmacokinetics analysis

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    93 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Low dose of BIBR 277
    Arm Type
    Experimental
    Arm Title
    Medium dose of BIBR 277
    Arm Type
    Experimental
    Arm Title
    High dose of BIBR 277
    Arm Type
    Experimental
    Intervention Type
    Drug
    Intervention Name(s)
    Low dose of BIBR 277
    Intervention Type
    Drug
    Intervention Name(s)
    Medium dose of BIBR 277
    Intervention Type
    Drug
    Intervention Name(s)
    High dose of BIBR 277
    Primary Outcome Measure Information:
    Title
    Area under the concentration-time curve of BIBR 277 in plasma from 0 to 24 hours (AUC0-24hr)
    Time Frame
    Pre-dose up to 24 hours after start of treatment
    Title
    Mean residence time of BIBR 277 in the body from 0 to 24 hours (MRT0-24hr)
    Time Frame
    Pre-dose up to 24 hours after start of treatment
    Title
    Maximum measured concentration of BIBR 277 in plasma (Cmax)
    Time Frame
    Pre-dose up to 24 hours after start of treatment
    Title
    Time from dosing to the maximum concentration of BIBR 277 in plasma (tmax)
    Time Frame
    Pre-dose up to 24 hours after start of treatment
    Title
    Terminal elimination half-time of BIBR 277 in plasma (t1/2)
    Time Frame
    Pre-dose up to 24 hours after start of treatment
    Secondary Outcome Measure Information:
    Title
    Changes from baseline in blood pressure (systolic, diastolic, and mean)
    Time Frame
    Pre-dose up to 14 days after start of treatment
    Title
    Changes from baseline in pulse rate
    Time Frame
    Pre-dose up to 14 days after start of treatment
    Title
    Number of patients with adverse events
    Time Frame
    Up to 29 days
    Title
    Changes from baseline in laboratory test values
    Time Frame
    Pre-dose up to 14 days after start of treatment

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    20 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Age: >=20 years Sex: Either male or female Patient status: Either inpatient or outpatient, provided that the patient was available for hospitalisation from the day before the trial medication administration until the morning of the day after administration BP: Sitting systolic and diastolic blood pressures (SBP and DBP) taken the day before administration should be >= 150 mmHg and >= 90 mmHg, respectively. Patients undergoing treatment with other antihypertensives were not excluded provided the above criteria were satisfied. Exclusion Criteria: Malignant hypertension Renovascular hypertension Severe heart failure (NYHA functional class III - IV), unstable angina pectoris, or history of myocardial infarction (within 6 months of onset) Atrioventricular conduction disturbance (degree II to III), atrial fibrillation, or serious arrhythmia Symptoms of cerebrovascular disorder Serious hepatic dysfunction Renal function disorder (serum creatinine >= 4.0 mg/dL) Known hypersensitivity to angiotensin II receptor antagonists Hyperkalaemia (potassium >= 5.5 milliequivalents per liter (mEq/L)) Treatment with the other investigational drug within 6 months of initiation of the present study Pregnant, breast feeding, possibly pregnant or planning to become pregnant during this study Previous treatment with the trial medication of the present study Otherwise judged ineligible by the investigator

    12. IPD Sharing Statement

    Links:
    URL
    http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.268_U04-3141.pdf
    Description
    Related Info

    Learn more about this trial

    Pharmacokinetics of BIBR 277 in Hypertensive Patients

    We'll reach out to this number within 24 hrs